Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | EIF4E | P06730 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508503 | 0.85 | TSHR (0.57) | ALDH1A1TP53VCAM1XDHSLC22A12 | |
| SCHEMBL21056017 | 0.85 | VCAM1 (0.47) | ALDH1A1TP53MAPTLMNAVCAM1 | |
| SCHEMBL3211886 | 0.83 | CASP1 (0.55) | ALDH1A1MAPTLMNAVCAM1PPARG | |
| SCHEMBL30818930 | 0.83 | CASP1 (0.55) | ALDH1A1MAPTLMNAVCAM1PPARG | |
| SCHEMBL3157619 | 0.82 | XDH (0.53) | ALDH1A1TDP1POLBXDHSLC22A12 | |
| SCHEMBL30819065 | 0.81 | PPARG (0.51) | ALDH1A1MAPTLMNAVCAM1PPARG | |
| SCHEMBL1783561 | 0.81 | ALDH1A1 (0.57) | ALDH1A1TP53TDP1KDM4ENPC1 | |
| SCHEMBL3820471 | 0.79 | SMN1; SMN2 (0.50) | ALDH1A1VCAM1PPARGSMN1; SMN2FLT1 | |
| SCHEMBL1179997 | 0.79 | MEN1 (0.49) | ALDH1A1TP53KDM4EMAPTLMNA | |
| SCHEMBL30902488 | 0.78 | HNF4A (0.62) | ALDH1A1TDP1KDM4EXDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115746704-B | Steel bridge deck composite structure with excellent corrosion resistance | 保利长大工程有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-115746704-A | Steel bridge deck composite structure with excellent corrosion resistance | 保利长大工程有限公司 | 2023-03-07 | — | — | CN | claimed |
| EP-4653053-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4426434-B1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250197357-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250186425-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-06-12 | — | — | US | disclosed |
| CN-119930513-A | PPARG modulators | 杭州邦顺制药有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119677720-A | PPARG inverse agonists and uses thereof | 弗拉雷治疗公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250084038-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-03-13 | — | — | US | disclosed |
| CN-119585237-A | PPARG inverse agonists and uses thereof | 弗拉雷治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4490147-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| EP-2533783-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186425-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | ALDH1A1 1455/4885TP53 1298/4885TDP1 3127/4885 |
| US-20080280876-A1 | Novel oxadiazole compounds | S1PR3, S1PR1, S1PR2 | ALDH1A1 4044/4885TP53 4155/4885TDP1 2946/4885 |
| US-20250084038-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | ALDH1A1 1367/4885TP53 1398/4885TDP1 3185/4885 |
| US-20130059883-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | ALDH1A1 1152/4885TP53 1320/4885TDP1 2861/4885 |
| US-20250197357-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | ALDH1A1 1455/4885TP53 1298/4885TDP1 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.